Biond Biologics is pleased to participate in the BIO International Convention, the world’s largest biotechnology partnering event, bringing together more than 20,000 leaders from across the global biotech and pharmaceutical ecosystem. BIO provides a unique opportunity to connect with partners, investors, and industry leaders who are shaping the future of biotechnology.
Our VP of Business Development, Dr. Tal Sines, will be attending to discuss Biond’s growing portfolio of first-in-class immunotherapies, including BND-22, currently in Phase 2 clinical development, and BND-67, our novel anti-CD28 shedding antibody currently being evaluated in a first-in-human study.
https://convention.bio.org/
